⁶⁴Cu-based Radiopharmaceuticals in Molecular Imaging

Area of Science:

• Nuclear Medicine
• Radiochemistry
• Biomolecular Imaging

Background:

• Copper-64 (Cu-64) is a radioisotope with a 12.7-hour half-life, suitable for medical applications due to its decay characteristics (19% β+, 38% β-).
• Its versatile coordination chemistry enables conjugation with various biomolecules, including antibodies, proteins, and peptides.
• Cu-64 can be produced via cyclotron or reactor-based methods.

Purpose of the Study:

• To review the properties and applications of Copper-64 (Cu-64) in nuclear medicine.
• To summarize commonly utilized biomarkers for Cu-64 radiolabeling.
• To highlight the potential of Cu-64 in both diagnostic imaging and therapeutic interventions.

Main Methods:

• Literature review of studies involving Copper-64 (Cu-64) applications.
• Analysis of radiolabeling strategies and chelator systems for Cu-64.
• Compilation of data on Cu-64 production methods (cyclotron and reactor).

Main Results:

• Copper-64's unique decay profile supports its use in positron emission tomography (PET) imaging and targeted radionuclide therapy.
• Established copper coordination chemistry facilitates its linkage to a wide array of biologically relevant molecules.
• Commonly used biomarkers for Cu-64 radiolabeling were identified and summarized.

Conclusions:

• Copper-64 is a promising theranostic radionuclide with broad applicability in oncology and other fields.
• The choice of chelator and targeting biomolecule is critical for optimizing Cu-64-based diagnostic and therapeutic efficacy.
• Further research into novel biomarkers and production methods will enhance the clinical utility of Cu-64.